Figure 4
Figure 4. PBMCs primed by αDEC-205-EBNA1 control EBV infection. Bulk PBMCs were pulsed with medium, 5 μg/mL αDEC-205-EBNA1, or control Ig-EBNA1 in combination with poly(I:C) and 10 U/mL IL-2. After 9 days, the cells were restimulated and expanded with an EBNA1 peptide library for an additional 6 days at which point autologous EBV-infected B cells were added into the culture and supplemented with 10 U/mL IL-2, 10 ng/mL IL-7, and 10 ng/mL IL-15. (A) After 16 days of coculture, outgrowth of EBV-infected B cells was assessed by flow cytometric analysis of CD19+ CD23+ double-positive cells. Representative data of 6 experiments are shown. Percentages on plots are of total cells within respective gates. (B) Summary of EBV-infected B-cell regression for 6 different donors.

PBMCs primed by αDEC-205-EBNA1 control EBV infection. Bulk PBMCs were pulsed with medium, 5 μg/mL αDEC-205-EBNA1, or control Ig-EBNA1 in combination with poly(I:C) and 10 U/mL IL-2. After 9 days, the cells were restimulated and expanded with an EBNA1 peptide library for an additional 6 days at which point autologous EBV-infected B cells were added into the culture and supplemented with 10 U/mL IL-2, 10 ng/mL IL-7, and 10 ng/mL IL-15. (A) After 16 days of coculture, outgrowth of EBV-infected B cells was assessed by flow cytometric analysis of CD19+ CD23+ double-positive cells. Representative data of 6 experiments are shown. Percentages on plots are of total cells within respective gates. (B) Summary of EBV-infected B-cell regression for 6 different donors.

Close Modal

or Create an Account

Close Modal
Close Modal